Skip to Content

Kynamro (mipomersen) Disease Interactions

There are 2 disease interactions with Kynamro (mipomersen):

Major

Mipomersen (applies to Kynamro) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Mipomersen is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or active liver disease, including unexplained persistent elevations of serum transaminases. This agent can cause elevations in transaminases and hepatic steatosis, and could induce steatohepatitis, which could progress to cirrhosis. It is recommended to measure a full liver panel to include ALT, AST, total bilirubin, and alkaline phosphatase before initiation of treatment. If transaminase elevations are accompanied by clinical symptoms of liver injury (e.g., nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin >= 2 times ULN, or active liver disease, discontinue treatment and identify the probable cause.

Moderate

Mipomersen (applies to Kynamro) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The use of mipomersen is not recommended in patients with severe renal impairment, clinically significant proteinuria or on renal dialysis. The safety and efficacy of this agent has not been established in patients with renal impairment or undergoing renal dialysis. Care should be exercised when using this agent in patients with renal dysfunction.

Kynamro (mipomersen) drug interactions

There are 284 drug interactions with Kynamro (mipomersen)

Kynamro (mipomersen) alcohol/food interactions

There is 1 alcohol/food interaction with Kynamro (mipomersen)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.